Toward Customized Trastuzumab in HER-2/neu-Overexpressing Non-Small-Cell Lung Cancers
- 1 April 2004
- journal article
- editorial
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 22 (7), 1171-1173
- https://doi.org/10.1200/jco.2004.01.904
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Trastuzumab in the Treatment of Advanced Non-Small-Cell Lung Cancer: Is There a Role? Focus on Eastern Cooperative Oncology Group Study 2598Journal of Clinical Oncology, 2004
- Transcripts in pretreatment biopsies from a three-arm randomized trial in metastatic non-small-cell lung cancerOncogene, 2003
- Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitorsOncogene, 2003
- Quantification of chemotherapeutic target gene mRNA expression in human breast cancer biopsies: Comparison of real‐time reverse transcription‐PCR vs. Relative quantification reverse transcription‐PCR utilizing DNA sequencer analysis of PCR productsJournal of Clinical Laboratory Analysis, 2003
- Correlation between encoded protein overexpression and copy number of the HER2 gene with survival in non‐small cell lung cancerInternational Journal of Cancer, 2002
- AKT2 is frequently upregulated in HER-2/neu-positive breast cancers and may contribute to tumor aggressiveness by enhancing cell survivalOncogene, 2002
- Efficacy and Safety of Trastuzumab as a Single Agent in First-Line Treatment of HER2-Overexpressing Metastatic Breast CancerJournal of Clinical Oncology, 2002
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2New England Journal of Medicine, 2001
- Trastuzumab in the Treatment of Metastatic Breast CancerCirculation, 2000
- Correlation of Intrinsic Chemoresistance of Non-Small-Cell Lung Cancer Cell Lines With HER-2/neu Gene Expression but Not With ras Gene MutationsJNCI Journal of the National Cancer Institute, 1993